David Alan Rizzieri, MD

Professor of Medicine
Member of the Duke Cancer Institute
Campus mail 1149 N Pavilion, Durham, NC 27710
Phone (919) 668-1040
Email address david.rizzieri@duke.edu

My research interests focus on the care of patients with hematologic malignancies, both with and without the use of bone marrow or stem cell transplantation. I focus my research efforts on new approaches to manipulate minimal residual disease.

Recent endeavors have included:

  1. Phase one trials with novel anti-cancer agents targeting aurora kinases, tyrosine kinases, mtor, VEGF, and raf/ras pathways 
  2. New monoclonal antibodies targeting tumor stroma rather than cellular antigens 
  3. Investigating new antibody targets, i.e. CD123, endoglin, or tenascin for hematologic malignancies 
  4. Aggressive therapy and transplantation for mantle cell lymphoma 
  5. Antiangiogenesis therapy for patients with NHL 
  6. Nonablative allogeneic transplantation therapy with matched or mismatched donors followed by immune modulation

Education and Training

  • Fellow in Hematology/Oncology, Medicine, Duke University, 1994 - 1997
  • Medical Resident, Medicine, Duke University, 1991 - 1994
  • M.D., University of Rochester, 1991

Publications

Kam, Angel Y. F., Sadhna O. Piryani, Chad M. McCall, Hee Su Park, David A. Rizzieri, and Phuong L. Doan. “Targeting High Mobility Group Box-1 (HMGB1) Promotes Cell Death in Myelodysplastic Syndrome..” Clin Cancer Res 25, no. 13 (July 1, 2019): 4155–67. https://doi.org/10.1158/1078-0432.CCR-18-3517.

PMID
30952643
Full Text

Lin, Kevin H., Abigail Xie, Justine C. Rutter, Yeong-Ran Ahn, Julia M. Lloyd-Cowden, Amanda G. Nichols, Ryan S. Soderquist, et al. “Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity..” Cell Metab 29, no. 5 (May 7, 2019): 1217-1231.e7. https://doi.org/10.1016/j.cmet.2019.01.011.

PMID
30773463
Full Text

Pemmaraju, Naveen, Andrew A. Lane, Kendra L. Sweet, Anthony S. Stein, Sumithira Vasu, William Blum, David A. Rizzieri, et al. “Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm..” N Engl J Med 380, no. 17 (April 25, 2019): 1628–37. https://doi.org/10.1056/NEJMoa1815105.

PMID
31018069
Full Text

Hudson, Kathryn E., David Rizzieri, Samantha M. Thomas, Thomas W. LeBlanc, Zachary Powell, Louis Diehl, Joseph O. Moore, Carlos DeCastro, and Anne W. Beaven. “Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study..” Br J Haematol 184, no. 4 (February 2019): 647–50. https://doi.org/10.1111/bjh.15138.

PMID
29468651
Full Text

Berdeja, J. G., M. C. Heinrich, S. R. Dakhil, S. L. Goldberg, M. Wadleigh, P. Kuriakose, J. Cortes, et al. “Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis.” Leukemia and Lymphoma, January 1, 2019. https://doi.org/10.1080/10428194.2019.1590569.

Full Text

Uy, Geoffrey L., Michael P. Rettig, Norbert Vey, John Godwin, Matthew C. Foster, David A. Rizzieri, Martha L. Arellano, et al. “Phase 1 Cohort Expansion of Flotetuzumab, a CD123xCD3 Bispecific Dart (R) Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML).” In Blood, Vol. 132. AMER SOC HEMATOLOGY, 2018. https://doi.org/10.1182/blood-2018-99-117085.

Full Text

Pemmaraju, Naveen, Andrew A. Lane, Kendra L. Sweet, Anthony S. Stein, Sumithira Vasu, William Blum, David A. Rizzieri, et al. “Results of Pivotal Phase 2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).” In Blood, Vol. 132. AMER SOC HEMATOLOGY, 2018. https://doi.org/10.1182/blood-2018-99-118966.

Full Text

Sorror, Mohamed L., Barry E. Storer, Aaron T. Gerds, Bruno C. Medeiros, Paul J. Shami, John P. Galvin, Kehinde U. Adekola, et al. “Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study.” In Blood, Vol. 132. AMER SOC HEMATOLOGY, 2018. https://doi.org/10.1182/blood-2018-99-112672.

Full Text

Sorror, Mohamed L., Barry E. Storer, Aaron T. Gerds, Bruno C. Medeiros, Paul J. Shami, John P. Galvin, Kehinde U. Adekola, et al. “Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study.” In Blood, Vol. 132. AMER SOC HEMATOLOGY, 2018. https://doi.org/10.1182/blood-2018-99-113094.

Full Text

Cook, Rachel J., Tamara Moyo, Jane L. Liesveld, David A. Rizzieri, Eytan M. Stein, Stephane De Botton, Gail J. Roboz, et al. “Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).” In Blood, Vol. 132. AMER SOC HEMATOLOGY, 2018. https://doi.org/10.1182/blood-2018-99-111285.

Full Text

Pages